129 related articles for article (PubMed ID: 7493140)
1. Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Advantages of using constant denaturant gel electrophoresis in mutation detection.
Andersen TI; Børresen AL
Diagn Mol Pathol; 1995 Sep; 4(3):203-11. PubMed ID: 7493140
[TBL] [Abstract][Full Text] [Related]
2. Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations.
Børresen AL; Hovig E; Smith-Sørensen B; Malkin D; Lystad S; Andersen TI; Nesland JM; Isselbacher KJ; Friend SH
Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8405-9. PubMed ID: 1924299
[TBL] [Abstract][Full Text] [Related]
3. Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families.
Zelada-Hedman M; Børresen-Dale AL; Claro A; Chen J; Skoog L; Lindblom A
Br J Cancer; 1997; 75(8):1201-4. PubMed ID: 9099970
[TBL] [Abstract][Full Text] [Related]
4. Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis.
Valgardsdottir R; Tryggvadottir L; Steinarsdottir M; Olafsdottir K; Jonasdottir S; Jonasson JG; Ogmundsdottir HM; Eyfjörd JE
APMIS; 1997 Feb; 105(2):121-30. PubMed ID: 9113074
[TBL] [Abstract][Full Text] [Related]
5. Mutation screening of the TP53 gene by temporal temperature gradient gel electrophoresis.
Sørlie T; Johnsen H; Vu P; Lind GE; Lothe R; Børresen-Dale AL
Methods Mol Biol; 2005; 291():207-16. PubMed ID: 15502225
[TBL] [Abstract][Full Text] [Related]
6. Mutation screening of the TP53 gene by temporal temperature gel electrophoresis (TTGE).
Sørlie T; Johnsen H; Vu P; Lind GE; Lothe R; Børresen-Dale AL
Methods Mol Biol; 2014; 1105():315-24. PubMed ID: 24623239
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis.
Thorlacius S; Thorgilsson B; Björnsson J; Tryggvadottir L; Börresen AL; Ogmundsdottir HM; Eyfjörd JE
Eur J Cancer; 1995 Oct; 31A(11):1856-61. PubMed ID: 8541113
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material.
Gretarsdottir S; Tryggvadottir L; Jonasson JG; Sigurdsson H; Olafsdottir K; Agnarsson BA; Ogmundsdottir H; Eyfjörd JE
Br J Cancer; 1996 Aug; 74(4):555-61. PubMed ID: 8761369
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of TP53 alterations in breast carcinoma.
Andersen TI; Holm R; Nesland JM; Heimdal KR; Ottestad L; Børresen AL
Br J Cancer; 1993 Sep; 68(3):540-8. PubMed ID: 8102535
[TBL] [Abstract][Full Text] [Related]
10. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer.
Overgaard J; Yilmaz M; Guldberg P; Hansen LL; Alsner J
Acta Oncol; 2000; 39(3):327-33. PubMed ID: 10987229
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas.
Kringen P; Bergamaschi A; Due EU; Wang Y; Tagliabue E; Nesland JM; Nehman A; Tönisson N; Børresen-Dale AL
Biotechniques; 2005 Nov; 39(5):755-61. PubMed ID: 16312222
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors.
Lothe RA; Fossli T; Danielsen HE; Stenwig AE; Nesland JM; Gallie B; Børresen AL
J Natl Cancer Inst; 1992 Jul; 84(14):1100-8. PubMed ID: 1619684
[TBL] [Abstract][Full Text] [Related]
13. TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast.
Chitemerere M; Andersen TI; Holm R; Karlsen F; Børresen AL; Nesland JM
Breast Cancer Res Treat; 1996; 41(2):103-9. PubMed ID: 8944328
[TBL] [Abstract][Full Text] [Related]
14. Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE).
Smith-Sørensen B; Gebhardt MC; Kloen P; McIntyre J; Aguilar F; Cerutti P; Børresen AL
Hum Mutat; 1993; 2(4):274-85. PubMed ID: 8401536
[TBL] [Abstract][Full Text] [Related]
15. Mutation analyses of KRAS exon 1 comparing three different techniques: temporal temperature gradient electrophoresis, constant denaturant capillary electrophoresis and allele specific polymerase chain reaction.
Bjørheim J; Lystad S; Lindblom A; Kressner U; Westring S; Wahlberg S; Lindmark G; Gaudernack G; Ekstrøm P; Røe J; Thilly WG; Børresen-Dale AL
Mutat Res; 1998 Jul; 403(1-2):103-12. PubMed ID: 9726011
[TBL] [Abstract][Full Text] [Related]
16. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.
Langerød A; Zhao H; Borgan Ø; Nesland JM; Bukholm IR; Ikdahl T; Kåresen R; Børresen-Dale AL; Jeffrey SS
Breast Cancer Res; 2007; 9(3):R30. PubMed ID: 17504517
[TBL] [Abstract][Full Text] [Related]
17. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutations do not correlate with locoregional recurrence in stage I tongue carcinomas.
Högmo A; Börresen-Dale AL; Blegen H; Lindholm J; Kuylenstierna R; Auer G; Munck-Wikland E
Anticancer Res; 1999; 19(4C):3433-8. PubMed ID: 10629631
[TBL] [Abstract][Full Text] [Related]
19. Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas.
Bukholm IK; Nesland JM; Kåresen R; Jacobsen U; Børresen AL
J Pathol; 1997 Feb; 181(2):140-5. PubMed ID: 9120716
[TBL] [Abstract][Full Text] [Related]
20. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.
Thorlacius S; Börresen AL; Eyfjörd JE
Cancer Res; 1993 Apr; 53(7):1637-41. PubMed ID: 8453635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]